NCT00412412View on ClinicalTrials.gov

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Breast Cancer
Interventions
DRUG

CNF2024

Oral doses of CNF2024 as specified in the protocol.

DRUG

CNF2024 + trastuzumab

Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.

Trial Locations (3)

10021

Research Site, New York

33612

Research Site, Tampa

77030

Research site, Houston

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY